Über uns
Über uns
Führungsteam
Partnerschaften
Unsere Standorte
Technologie
Technologie
Produktion
Publikationen
Pipeline
Newsroom
News
Events
Downloads
Investor Relations
Überblick
Aktieninformation
Analysten-Coverage
Hauptversammlung
Finanzberichte
Corporate Governance
E-Mail Alert
Karriere
Werden Sie Teil der RNA people
Ausbildung
Aktuelle Stellenangebote
DE
Mechanism of Action
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
by Sovereign
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
by Sovereign
Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway
by Sovereign
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
by Sovereign
Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent
by Sovereign
Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA
by Sovereign
Characterization of the ribonuclease activity on the skin surface
by Sovereign
Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro
by Sovereign
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas
by Sovereign
Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA
by Sovereign
1
2
3